# A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult

> **NCT06313697** · PHASE1 · UNKNOWN · sponsor: **Genrix (Shanghai) Biopharmaceutical Co., Ltd.** · enrollment: 132 (estimated)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** GR2102 injection
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT06313697
- **Lead sponsor:** Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-23
- **Primary completion:** 2025-01-06
- **Final completion:** 2025-12-06
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06313697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06313697, "A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06313697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*